Deals, Insiders

The top 10 hit parade of biopharma licensing deals for 2014-2017

The Merck KGaA logo stands illuminated at dusk outside the pharmaceutical company's headquarters in Darmstadt, Germany, on November 3, 2016 Bloomberg


Bayer’s recent deal to partner with Loxo for $400 million in cash inspired this latest analysis of top deals. I thought it would make the top 10, but after reviewing the upfront money paid for licensing pacts over the past three years, it just barely missed the list you’ll see below.

Biobucks remain the currency of choice in dealmaking, but it’s the hard upfront cash that tells us what kind of drugs are valued the highest. Not surprisingly, that covers three currently marketed drugs and seven experimental therapies for a total of $7.1 billion in down payments.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 21,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

Immuno Oncology 360